Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25336473 | 0.96 | KDM4E (0.49) | KDM4EALDH1A1PKMHTR1ABCHE | |
| Oxalic Acid SCHEMBL30010515 | 0.94 | KDM4E (0.55) | KDM4EALDH1A1PKMHTR1ABCHE | |
| SCHEMBL21566193 | 0.86 | HTR1A (0.46) | KDM4EALDH1A1PKMHTR1ABCHE | |
| SCHEMBL21140538 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1PKMHTR1ABCHE | |
| SCHEMBL1289738 | 0.83 | ALDH1A1 (0.47) | KDM4EALDH1A1PKMBCHECHRM5 | |
| SCHEMBL30442024 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1PKMBCHECHRM5 | |
| SCHEMBL14067261 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1PKMBCHECHRM5 | |
| SCHEMBL14590482 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1PKMBCHECHRM5 | |
| Hydrochloric Acid SCHEMBL1289689 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1PKMBCHECHRM5 | |
| Bromide SCHEMBL10773361 | 0.80 | BCHE (0.61) | KDM4EALDH1A1PKMBCHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114144408-B | Large scale preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide hemisuccinate and process and intermediates for preparing 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide acetate | 伊莱利利公司 | 2025-04-15 | — | — | CN | claimed |
| EP-3996713-B1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE | LILLY CO ELI (US) | 2024-12-04 | — | — | EP | claimed |
| EP-4410784-A2 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE | Eli Lilly and Company (US) | 2024-08-07 | — | — | EP | claimed |
| US-20240059666-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2024-02-22 | — | — | US | claimed |
| US-11827618-B2 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate | ELI LILLY AND COMPANY | 2023-11-28 | — | — | US | claimed |
| US-20230250076-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-08-10 | — | — | US | claimed |
| US-20230250075-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-08-10 | — | — | US | claimed |
| US-20230137090-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-05-04 | — | — | US | claimed |
| EP-3996713-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3994131-A1 | 2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN | Moehs Ibérica, S.L. (ES) | 2022-05-11 | — | — | EP | claimed |
| CN-114144408-A | Process and intermediates for large scale preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide hemisuccinate and preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide acetate | 伊莱利利公司 | 2022-03-04 | — | — | CN | claimed |
| US-8697876-B2 | Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists | COLUCID PHARMACEUTICALS, INC. (US) | 2014-04-15 | — | — | US | claimed |
| US-20130072524-A1 | Compositions And Methods Of Synthesis Of Pyridinolypiperidine 5-HT1F Agonists | APTUIT (EDINBURGH) LTD. (GB) | 2013-03-21 | — | — | US | claimed |
| WO-2011123654-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS OF PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS | COLUCID PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| CN-114144408-B | Large scale preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide hemisuccinate and process and intermediates for preparing 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide acetate | 伊莱利利公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250019363-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2025-01-16 | — | — | US | disclosed |
| EP-3996713-B1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE | LILLY CO ELI (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059666-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | KDM4E 146/4885ALDH1A1 1176/4885PKM 1169/4885 |
| US-20230250075-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | KDM4E 146/4885ALDH1A1 1176/4885PKM 1169/4885 |
| US-11827618-B2 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KDM4D, KDM5B | KDM4E 36/4885ALDH1A1 1147/4885PKM 542/4885 |
| US-20130072524-A1 | Compositions And Methods Of Synthesis Of Pyridinolypiperidine 5-HT1F Agonists | HTR1F, HTR1A, HTR1D | KDM4E 725/4885ALDH1A1 2482/4885PKM 1977/4885 |
| US-20230137090-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, HTR2A | KDM4E 181/4885ALDH1A1 1237/4885PKM 1285/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | KDM4E 1488/4885ALDH1A1 904/4885PKM 1562/4885 |
| US-20250019363-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | KDM4E 146/4885ALDH1A1 1176/4885PKM 1169/4885 |
| US-20230250076-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | KDM4E 146/4885ALDH1A1 1176/4885PKM 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.